Dr. Sulaiman Al Habib Medical Services Group Zukünftiges Wachstum
Future Kriterienprüfungen 4/6
Dr. Sulaiman Al Habib Medical Services Group wird ein jährliches Gewinn- und Umsatzwachstum von 14.8% bzw. 15.3% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 15.7% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 37.6% betragen.
Wichtige Informationen
14.6%
Wachstumsrate der Gewinne
15.1%
EPS-Wachstumsrate
| Healthcare Gewinnwachstum | 14.8% |
| Wachstumsrate der Einnahmen | 15.2% |
| Zukünftige Eigenkapitalrendite | 37.3% |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 04 Jun 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Dr. Sulaiman Al Habib Medical Services Group Company (TADAWUL:4013) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
May 03
Earnings Beat: Dr. Sulaiman Al Habib Medical Services Group Company Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Apr 27Recent updates
Dr. Sulaiman Al Habib Medical Services Group's (TADAWUL:4013) Shareholders Will Receive A Bigger Dividend Than Last Year
May 23Dr. Sulaiman Al Habib Medical Services Group (TADAWUL:4013) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
May 08Dr. Sulaiman Al Habib Medical Services Group Company (TADAWUL:4013) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
May 03Subdued Growth No Barrier To Dr. Sulaiman Al Habib Medical Services Group Company's (TADAWUL:4013) Price
Apr 29There's Been No Shortage Of Growth Recently For Dr. Sulaiman Al Habib Medical Services Group's (TADAWUL:4013) Returns On Capital
Mar 15Dr. Sulaiman Al Habib Medical Services Group's (TADAWUL:4013) Dividend Will Be SAR1.15
Feb 22With EPS Growth And More, Dr. Sulaiman Al Habib Medical Services Group (TADAWUL:4013) Makes An Interesting Case
Feb 20Dr. Sulaiman Al Habib Medical Services Group Company's (TADAWUL:4013) Price Is Out Of Tune With Earnings
Jan 09We Like These Underlying Return On Capital Trends At Dr. Sulaiman Al Habib Medical Services Group (TADAWUL:4013)
Nov 28We Think That There Are Issues Underlying Dr. Sulaiman Al Habib Medical Services Group's (TADAWUL:4013) Earnings
Nov 07Dr. Sulaiman Al Habib Medical Services Group's (TADAWUL:4013) Shareholders Will Receive A Bigger Dividend Than Last Year
Nov 02Here's Why Dr. Sulaiman Al Habib Medical Services Group (TADAWUL:4013) Has Caught The Eye Of Investors
Sep 21Dr. Sulaiman Al Habib Medical Services Group (TADAWUL:4013) Is Doing The Right Things To Multiply Its Share Price
Aug 10Here's Why We Think Dr. Sulaiman Al Habib Medical Services Group (TADAWUL:4013) Is Well Worth Watching
Jun 17Dr. Sulaiman Al Habib Medical Services Group's (TADAWUL:4013) Shareholders Will Receive A Bigger Dividend Than Last Year
May 12Returns At Dr. Sulaiman Al Habib Medical Services Group (TADAWUL:4013) Are On The Way Up
May 06Here's Why We Think Dr. Sulaiman Al Habib Medical Services Group (TADAWUL:4013) Might Deserve Your Attention Today
Mar 13Dr. Sulaiman Al Habib Medical Services Group's (TADAWUL:4013) Returns On Capital Are Heading Higher
Jan 30With EPS Growth And More, Dr. Sulaiman Al Habib Medical Services Group (TADAWUL:4013) Makes An Interesting Case
Dec 07Dr. Sulaiman Al Habib Medical Services Group (TADAWUL:4013) Is Doing The Right Things To Multiply Its Share Price
Oct 23If EPS Growth Is Important To You, Dr. Sulaiman Al Habib Medical Services Group (TADAWUL:4013) Presents An Opportunity
Sep 08Estimating The Intrinsic Value Of Dr. Sulaiman Al Habib Medical Services Group Company (TADAWUL:4013)
Aug 24Why Dr. Sulaiman Al Habib Medical Services Group Company (TADAWUL:4013) Could Be Worth Watching
Aug 08Dr. Sulaiman Al Habib Medical Services Group (TADAWUL:4013) Has More To Do To Multiply In Value Going Forward
Jul 12Does Dr. Sulaiman Al Habib Medical Services Group (TADAWUL:4013) Deserve A Spot On Your Watchlist?
May 31A Look At The Fair Value Of Dr. Sulaiman Al Habib Medical Services Group Company (TADAWUL:4013)
May 17Dr. Sulaiman Al Habib Medical Services Group (TADAWUL:4013) Will Pay A Larger Dividend Than Last Year At ر.س0.83
Apr 28Should You Think About Buying Dr. Sulaiman Al Habib Medical Services Group Company (TADAWUL:4013) Now?
Apr 09Return Trends At Dr. Sulaiman Al Habib Medical Services Group (TADAWUL:4013) Aren't Appealing
Mar 06Here's Why I Think Dr. Sulaiman Al Habib Medical Services Group (TADAWUL:4013) Is An Interesting Stock
Feb 16Returns On Capital At Dr. Sulaiman Al Habib Medical Services Group (TADAWUL:4013) Have Stalled
Dec 05Do Dr. Sulaiman Al Habib Medical Services Group's (TADAWUL:4013) Earnings Warrant Your Attention?
Nov 17Investors Could Be Concerned With Dr. Sulaiman Al Habib Medical Services Group's (TADAWUL:4013) Returns On Capital
Aug 30Here's Why I Think Dr. Sulaiman Al Habib Medical Services Group (TADAWUL:4013) Might Deserve Your Attention Today
Aug 01Estimating The Fair Value Of Dr. Sulaiman Al Habib Medical Services Group Company (TADAWUL:4013)
Jun 11Capital Allocation Trends At Dr. Sulaiman Al Habib Medical Services Group (TADAWUL:4013) Aren't Ideal
May 27Earnings Beat: Dr. Sulaiman Al Habib Medical Services Group Company Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Apr 27Here's Why I Think Dr. Sulaiman Al Habib Medical Services Group (TADAWUL:4013) Might Deserve Your Attention Today
Apr 06A Look At The Fair Value Of Dr. Sulaiman Al Habib Medical Services Group Company (TADAWUL:4013)
Feb 04Is Dr. Sulaiman Al Habib Medical Services Group Company's (TADAWUL:4013) Shareholder Ownership Skewed Towards Insiders?
Jan 14
Dr. Sulaiman Al Habib Medical Services Group Company (TADAWUL:4013) Is Yielding 1.5% - But Is It A Buy?
Dec 23Dr. Sulaiman Al Habib Medical Services Group Company's (TADAWUL:4013) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?
Nov 27Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2026 | 16,076 | 3,238 | 2,510 | 4,363 | 7 |
| 12/31/2025 | 14,416 | 2,731 | 1,720 | 3,536 | 9 |
| 12/31/2024 | 11,334 | 2,201 | -763 | 2,996 | 7 |
| 3/31/2024 | 9,723 | 2,108 | -758 | 3,291 | N/A |
| 12/31/2023 | 9,508 | 2,046 | -253 | 3,244 | N/A |
| 9/30/2023 | 9,276 | 1,962 | 60 | 3,072 | N/A |
| 6/30/2023 | 8,885 | 1,838 | 509 | 2,789 | N/A |
| 3/31/2023 | 8,627 | 1,750 | 1,219 | 2,932 | N/A |
| 12/31/2022 | 8,311 | 1,651 | 1,330 | 2,844 | N/A |
| 9/30/2022 | 8,025 | 1,593 | 838 | 2,411 | N/A |
| 6/30/2022 | 7,809 | 1,521 | 956 | 2,254 | N/A |
| 3/31/2022 | 7,547 | 1,448 | 1,067 | 2,419 | N/A |
| 12/31/2021 | 7,250 | 1,377 | 929 | 2,183 | N/A |
| 9/30/2021 | 6,974 | 1,311 | 1,156 | 2,441 | N/A |
| 6/30/2021 | 6,761 | 1,261 | 1,120 | 2,170 | N/A |
| 3/31/2021 | 6,213 | 1,128 | 1,219 | 2,183 | N/A |
| 12/31/2020 | 5,862 | 1,055 | 1,420 | 2,234 | N/A |
| 9/30/2020 | 5,575 | 1,008 | 1,219 | 1,871 | N/A |
| 6/30/2020 | 5,178 | 907 | 1,030 | 1,743 | N/A |
| 3/31/2020 | 5,132 | 883 | 503 | 1,155 | N/A |
| 12/31/2019 | 5,016 | 870 | 326 | 1,059 | N/A |
| 9/30/2019 | 4,816 | 825 | 843 | 1,549 | N/A |
| 6/30/2019 | 4,735 | 835 | 753 | 1,539 | N/A |
| 3/31/2019 | 4,646 | 819 | 1,005 | 1,760 | N/A |
| 12/31/2018 | 4,588 | 801 | 789 | 1,447 | N/A |
| 12/31/2017 | 4,687 | 658 | N/A | 1,058 | N/A |
| 12/31/2016 | 4,868 | 1,010 | N/A | 900 | N/A |
| 12/31/2015 | 5,123 | 1,329 | N/A | 922 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: 4013Das prognostizierte Gewinnwachstum (14.8% pro Jahr) liegt über der Sparquote (14.3%).
Ertrag vs. Markt: 4013Die Erträge des Unternehmens (14.8% pro Jahr) werden voraussichtlich schneller wachsen als der Markt SA (6.8% pro Jahr).
Hohe Wachstumserträge: 4013Die Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.
Einnahmen vs. Markt: 4013Die Einnahmen des Unternehmens (15.3% pro Jahr) werden voraussichtlich schneller wachsen als der Markt SA (-0.3% pro Jahr).
Hohe Wachstumseinnahmen: 4013Die Einnahmen des Unternehmens (15.3% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: 4013Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich hoch sein (37.6%)